iTind is a novel treatment for patients suffering from urinary symptoms associated with benign prostatic hyperplasia. It comprises a temporary implantable nickel device.
Extensive research has been conducted, and the findings demonstrate consistent positive results over a three-year period. This positions iTind as a compelling alternative to existing therapies for benign prostatic hyperplasia.
It is recommended for patients aged 50 and above, whose prostate is equal to or less than 60 cc, and who have a small or absent middle lobe. This treatment is particularly beneficial for patients experiencing obstructive urinary symptoms, such as frequent urination, dribbling, reduced urine stream strength, the need to strain while urinating, and a sensation of incomplete emptying. Additionally, it is suitable for individuals with increased nocturia.
The device itself has a “basket” shape. It is folded, inserted through the urethra into the bladder, and then unfolded in the prostatic urethra. Over the course of several days, the device exerts pressure that widens the prostatic urethra and the neck of the bladder, facilitating the smoother flow of urine. After five to seven days, the device is removed with the assistance of a catheter.
The benefits of iTind encompass the swiftness and efficacy of the treatment, with noticeable results within a few weeks. Furthermore, it is a low-risk, minimally invasive outpatient procedure performed under local anesthesia or sedation. Importantly, it preserves sexual and ejaculatory function.
Additionally, unlike other procedures, iTind does not entail the removal of prostate tissue or the need for a permanent device or implants. Patients do not experience any discomfort, nor are they required to wear a temporary urinary catheter.